ArticleCombinatorial chemistry & high throughput screening2026
An Analysis of Effective Components of Pulsatillae radix Using UHPLC-QTOF- MS/MS and Network Pharmacology to Investigate its Effects on Ulcerative Colitis.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPulsatillae radix (PR), a medicinal root plant and a well-known Chinese herbal remedy, is primarily used for its heat-clearing, detoxifying, blood-cooling, and antiinflammatory properties.
methodsThe constituents of PR were systematically analyzed using UHPLC-Q-TOFMS/ MS. Potential targets of active components were identified via the SwissTargetPrediction and PharmMapper databases, while (ulcerative colitis) UC-related disease targets were retrieved from GeneCard and other relevant databases. Overlapping targets between PR and UC were determined using Venn analysis. The STRING database was employed to generate a PPI network for the intersecting targets, and core targets were identified using the CytoNCA plugin. GO and KEGG pathway enrichment analyses were conducted using the DAVID platform. Lastly, molecular docking of key components with target proteins was carried out using PyMOL.
resultsA total of 27 active compounds, 237 drug targets, and 4622 disease targets were identified. Intersection analysis revealed 141 shared targets, while the PPI network identified 10 hub targets. GO and KEGG enrichment analyses indicated that the hub targets were primarily associated with phosphorylation, cytoplasmic functions, nuclear receptor activity, as well as pathways related to the AGE-RAGE products signaling, TCR signaling, lipid and cholesterol metabolism, and various cancer-related pathways. Molecular docking experiments demonstrated that (+)- pinoresinol, cichoric acid, β-ecdysone, pulsatilla saponin D, 23-HBA, and AB4 exhibited stable binding to PIK3R1, TLR4, and ESR1, with AB4 forming the most stable complex with ESR1. DISCUSSION: PR exerts therapeutic effects on UC through the synergistic actions of multicomponents (AB4, 23-HBA), multi-targets (ESR1, TLR4, PIK3R1), and multi-pathways (AGERAGE, TCR).
Indexed as
Identifiers
40375698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.